Pharmaceuticals

Bristol Myers Squibb

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Bristol Myers Squibb Shareholders Approve Management Proposals and Reject Independent Chairman Proposal

LJI Wealth Management LLC Buys More Shares of Bristol-Myers Squibb

Scotiabank Analyst Maintains Hold Rating for BMY

Robertson Stephens Increases Holdings in Bristol Myers Squibb

GC Wealth 大幅减持百时美施贵宝持股

Artemis Investment Management Increases Holdings in Bristol-Myers Squibb

Bristol Myers Squibb released FY2026 Q1 earnings on April 30 During-Market (EST), actual revenue USD 11.49 B (forecast USD 10.92 B), actual EPS USD 1.31 (forecast USD 1.1501)

Bristol Myers Squibb Reports Q1 EPS Exceeding Expectations

Bristol-Myers Squibb Exceeds Revenue Expectations in Q1

Bristol-Myers Squibb reports Q1 gross margin of 70.2%

Waypoint Wealth Counsel Increased Holdings in Bristol-Myers Squibb in Q4

Bristol Myers Squibb to release FY2026 Q1 earnings on April 30 During-Market EST, forecast revenue USD 10.91 B, EPS USD 1.1501

Bristol Myers Squibb Expands Collaboration With Foundation Medicine To Develop Next-Generation Sequencing Companion Diagnostic

Wall Street 禅 Raises BMY's Rating to Strong Buy

Bristol Myers Squibb CFO Sells 30,000 Shares

Bristol Myers Squibb Launches Drug Discounts on TrumpRx.gov

Bristol-Myers Squibb Announces Positive Results from Camzyos Phase III Clinical Trials in Adolescent Cardiomyopathy Patients

Amesite

InMed Pharmaceuticals

Meiwu Tech

Phoenix Asia

Co-Diagnostics

Rubico

Generation Income Properties

MetaVia

Virax Biolabs

Hub Cyber Security

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Johnson & Johnson

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

ABBV

ARKG

SBIO

In turbulent markets, investors favor high-dividend stocks. Benzinga highlights three healthcare stocks: AbbVie (3.30% yield), GSK (3.58% yield), and Bristol-Myers Squibb (4.40% yield). Analysts provide ratings and price targets, with AbbVie receiving an Overweight rating and a price target increase. GSK's stock was downgraded by Barclays but upgraded by Jefferies. Bristol-Myers Squibb announced a partnership for early-stage programs. Real-time updates are available on Benzinga's platform.

benzinga_article

Abbvie

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Piper Sandler Cos

Barclays

Jefferies Financial

Bank of America

Hengrui Pharma

HENGRUI PHARMA

GlaxoSmithKline plc

GSK plc Sponsored ADR

Bristol-Myers Squibb Company

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

LABU

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Merck

AstraZeneca

ProShares Ultra Health Care ETF

Direxion S&P Biotech Bull 3X

AstraZeneca PLC

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

IBBQ

Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

State Street

Legal & General Group Plc

State Street® US Equity Premium Inc ETF

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

HIMS

HIMY

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Invesco S&P 500 Equal Weight Health Care ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

SPDR S&P Health Equip

iShares US Healthcare Providers

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

ELIL

LLYX

This week's biotech highlights include Lilly's positive Phase 3b results for Zepbound, Rigel's licensing of the FDA-approved PROTAC therapy Veppanu, and Bristol Myers Squibb's $15.2 billion deal with Hengrui Pharma. Other notable updates include ATyr's refined Phase 3 path for Efzofitimod, Apyx's expanded FDA clearance for AYON, and argenx's label expansion for VYVGART. The week also saw various companies reporting positive clinical trial results.

rttnews

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Rigel Pharma

ATYR Pharma

Apyx Medical

Argenx

Alpha Tau Medical

Sellas Life Sciences

WORK Medical Tech

Arvinas

Pfizer

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal

Allworth Financial LP increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 106.4% in Q4, owning 217,248 shares valued at $11.7 million. Other institutional investors also raised their holdings. Analysts have set target prices ranging from $40 to $68, with a consensus rating of 'Hold' and an average target price of $61.31. The stock opened at $56.76, with a market cap of $115.91 billion.

Morgan Stanley

HSBC Holdings Plc

HSBC

HSBC HOLDINGS

ROYAL BANK OF CANADA

GRAIL

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

Bristol Myers Squibb Company $BMY Shares Acquired by Allworth Financial LP

Bristol Myers Squibb(BMY.US)